secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0000950170-25-018402
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes reports FY2024 revenue $1.56B, net income $372M; guides FY2025 rev $1.34-$1.43B
--------------------------------------------------------------------------------

- FY2024 total revenues $1.56B, proprietary net sales up 18% YoY to $1.08B; GAAP diluted EPS from cont. ops $2.20.
- Q4 proprietary net sales $307.7M: LYBALVI $77M (+37%), ARISTADA $96.6M (+16%), VIVITROL $134.1M (+31%).
- Year-end cash/investments $824.8M; debt-free after retiring $290M debt; repurchased $200M shares in 2024.
- FY2025 guidance: rev $1.34-$1.43B, GAAP net income $175-$205M, R&D spend up to $335M for pipeline.
- ALKS 2680 Phase 2 narcolepsy data expected H2 2025; Phase 2 in idiopathic hypersomnia planned; ALKS 4510/7290 Phase 1 starts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/0000950170-25-018402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/alks-20250212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-018402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer